These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11153678)

  • 81. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
    Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 83. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
    Gallego O; de Mendoza C; Pérez-Elías MJ; Guardiola JM; Pedreira J; Dalmau D; Gónzalez J; Moreno A; Arribas JR; Rubio A; García-Arata I; Leal M; Domingo P; Soriano V
    AIDS; 2001 Sep; 15(13):1701-6. PubMed ID: 11546946
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
    Wainberg MA; Lewis L; Salomon H; Gu Z; Keller A; Cammack N; Goldsmith J; Church J; Spira B; Wheeler S; Pizzo P
    Antivir Ther; 1996 Apr; 1(2):98-104. PubMed ID: 11321185
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Sequencing antiretroviral drugs.
    Soriano V
    AIDS; 2001 Mar; 15(5):547-51. PubMed ID: 11316990
    [No Abstract]   [Full Text] [Related]  

  • 88. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Incidence and impact of resistance against approved antiretroviral drugs.
    Pillay D; Taylor S; Richman DD
    Rev Med Virol; 2000; 10(4):231-53. PubMed ID: 10891871
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs.
    Dunne AL; Mitchell FM; Coberly SK; Hellmann NS; Hoy J; Mijch A; Petropoulos CJ; Mills J; Crowe SM
    AIDS; 2001 Aug; 15(12):1471-5. PubMed ID: 11504978
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Targeting HIV: antiretroviral therapy and development of drug resistance.
    Menéndez-Arias L
    Trends Pharmacol Sci; 2002 Aug; 23(8):381-8. PubMed ID: 12377580
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Secondary structure predictions of HIV-1 reverse transcriptase provide new insights into the development of drug-resistance genotypes.
    Fantini J; Tamalet C; Yahi N
    AIDS; 2001 Jun; 15(9):1191-2. PubMed ID: 11416728
    [No Abstract]   [Full Text] [Related]  

  • 93. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.
    Wang D; Hicks CB; Goswami ND; Tafoya E; Ribeiro RM; Cai F; Perelson AS; Gao F
    J Virol; 2011 Jul; 85(13):6403-15. PubMed ID: 21490094
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.
    Coull JJ; Turner D; Melby T; Betts MR; Lanier R; Margolis DM
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):423-34. PubMed ID: 11391161
    [TBL] [Abstract][Full Text] [Related]  

  • 95. How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
    De Clercq E
    AIDS; 1994 Jul; 8(7):1020-1. PubMed ID: 7524543
    [No Abstract]   [Full Text] [Related]  

  • 96. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy.
    Briones C; Mas A; Gómez-Mariano G; Altisent C; Menéndez-Arias L; Soriano V; Domingo E
    Virus Res; 2000 Jan; 66(1):13-26. PubMed ID: 10653914
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
    Derdelinckx I; Van Laethem K; Maes B; Schrooten Y; De Wit S; Florence E; Fransen K; Ribas SG; Marissens D; Moutschen M; Vaira D; Zissis G; Van Ranst M; Van Wijngaerden E; Vandamme AM
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1664-6. PubMed ID: 15577426
    [No Abstract]   [Full Text] [Related]  

  • 98. Antiretroviral therapy: state of the HAART.
    Vella S; Palmisano L
    Antiviral Res; 2000 Jan; 45(1):1-7. PubMed ID: 10774585
    [No Abstract]   [Full Text] [Related]  

  • 99. Inhibitors of HIV-1 reverse transcriptase.
    Parniak MA; Sluis-Cremer N
    Adv Pharmacol; 2000; 49():67-109. PubMed ID: 11013761
    [No Abstract]   [Full Text] [Related]  

  • 100. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
    Miller V; Sabin C; Hertogs K; Bloor S; Martinez-Picado J; D'Aquila R; Larder B; Lutz T; Gute P; Weidmann E; Rabenau H; Phillips A; Staszewski S
    AIDS; 2000 Dec; 14(18):2857-67. PubMed ID: 11153667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.